

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 21(17), 2013-2019 (1995)

COMMUNICATIONS

BIOADHESIVE POLYMER BUCCAL PATCHES FOR BUPRENORPHINE CONTROLLED DELIVERY: SOLUBILITY CONSIDERATION

Jian-Hwa Guo and K. M. Cooklock

3M Pharmaceuticals, 3M Center, 270-4S-02, St. Paul, MN 55144-1000

ABSTRACT

By using a two-roll milling method, a new bioadhesive polymer patch formulation for buprenorphine controlled delivery and consisting of polyisobutylene, polyisoprene, and Carbopol® 934P was prepared. Since solubility of drug in the polymer patches is the first factor which should be considered before to modify the feasibility of delivering drug through the buccal mucosa, the effects of α -cyclodextrin, β -cyclodextrin, sodium taurocholate, and sodium glycodeoxycholate on the solubility of buprenorphine were investigated, and β -cyclodextrin was found the strongest solubility enhancer of them. The drug release profiles were significantly affected by the drug loading and the existence of β -cyclodextrin. Increasing the drug loading and solubility enhancer would increase the drug release from the buccal polymer patches. The pH value change in the microenvironment of polymer patches during the hydration of Carbopol® 934P could even release 20% of drug from the polymer patches which didn't contain any solubility enhancer.

INTRODUCTION

Recently the buccal mucosa has been studied as a potential site for delivery of drug, because of its accessibility and low enzymatic activity. The buccal mucosa may offer alternate route of delivery for drugs including those that are metabolically unstable (1). The buccal mucosa was investigated as a potential site for drug delivery several decades ago and interest in this area for transmucosal drug administration is still growing (1-3).

Buprenorphine is a partial μ agonist opioid analgesic that is well absorbed by both the intramuscular and sublingual routes and is 25-50 times more potent than morphine (4). The drug's onset of action occurs rapidly, with maximum blood drug levels attained within five minutes of intramuscular injection. The duration of action of buprenorphine can be extended from the 4-5 hours obtained with a single intramuscular dose to 5-6 hours with the use of sublingual administration. The latter route is already being developed as an alternative to the injectable formulation (5).

The in-vitro characterization of a newly developed bioadhesive patch for controlled drug delivery via the buccal mucosa was investigated by Guo (6-7) and Scherrer, et al (8). The effects of different ratios of Carbopol[®] 934P, polyisobutylene, and polyisoprene on the surface properties, adhesion, and swelling of buccal patches were investigated. They had developed patches composed of Carbopol[®] 934P, polyisobutylene, and polyisoprene having physical properties that are required for the buccal controlled drug delivery.

Solubility of drug in the polymer patches is the first factor which should be considered before to modify the feasibility of delivering drug through the buccal mucosa. This paper describes the factors which would affect the solubility of buprenorphine, a partial μ agonist opioid analgesic, via the buccal mucosa, in the polymer patches, and the effects on the release of buprenorphine from those patches would be discussed as well.




FIGURE 1

The effect of β -cyclodextrin on the buprenorphine release from the CP/PIB/PIP=60/35/5 buccal patches.

MATERIALS AND METHODS

Preparation of polymer patches was as follows: a desired ratio of bioadhesive polymer Carbopol® (934P grade, BF Goodrich, Cleveland, OH) (CP), polyisobutylene (LMMH grade, EXXON Chemical Co., Houston, TX) (PIB), and polyisoprene (Goodyear Chemical Co., Akron, OH) (PIP) were mixed homogeneously with buprenorphine (Diosynge, NJ) and additive (α -cyclodextrin, β -cyclodextrin, sodium taurocholate, or sodium glycodeoxycholate) (Sigma, MO) by a two-roll mill. The elastomer polymer

Drug Dev Ind Pharm Downloaded from informahealthcare.com by Doris Yen on 02/27/15
For personal use only.




FIGURE 2

The effect of β -cyclodextrin and drug loading on the buprenorphine release from the CP/PIB/PIP=50/43.75/6.25 buccal patches.

mixture was compressed in a predetermined thickness, and appropriate sizes were punched out for in-vitro testing (6-7).

The in-vitro drug release through the hydrated polyvinyl pyrrolidone/cellulose acetate hydrogel film was conducted by using diffusion cells and were performed in phosphate buffer (pH=7) at 37°C. Aliquots were taken at various times up to 24 hours and assayed for buprenorphine free base or HCl salt by high-pressure liquid chromatography. The gradient system used in this study consisted of mobile phase, CH₃CN/16.6 mM CH₃(CH₂)₅SO₃Na aqueous solution/CH₃COOH, 70%/30%/1%, (v/v/v) at flow rate 1.5 ml/min.




FIGURE 3

The pH values of different CP-934P or CP-974P concentrations
(at pH 7 Phosphate Buffer).

RESULTS AND DISCUSSION

The effects of α -cyclodextrin, β -cyclodextrin, sodium taurocholate, and sodium glycodeoxycholate on the solubility of buprenorphine free base or HCl salt were investigated. β -cyclodextrin was found the strongest solubility enhancer of buprenorphine free base and HCl salt (β -cyclodextrin > α -cyclodextrin > sodium taurocholate > sodium glycodeoxycholate). The effects of β -cyclodextrin and drug loading on the buprenorphine free base or HCl salt release profiles from CP/PIB/PIP = 60/35/5 and CP/PIB/PIP = 50/43.75/6.25 formulations are demonstrated in Figures 1 and 2, respectively.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.